Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 107

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 107
---
 2023, in accordance with the Equity Line, the Company issued 92,073 and 333,271, shares of the Company’s Common Stock with aggregate proceeds to the Company of $112 and $567, respectively. As of December 31, 2024, and 2023, there were 3,281,032 and 3,188,959 shares of Common Stock issued and outstanding, respectively. 

 Warrants A summary of activity of the warrants during the years ended December 31, 2024, and 2023, is as follows:   Number of   Weighted Average   Weighted Average    shares  Exercise Price  Life (years) Outstanding, December 31, 2022  270,053  $64.16   2.05 Granted  -   -   - Expired  (27,420)  198.07   - Exercised  -   -   - Outstanding, December 31, 2023  242,633  $44.07   1.10 Granted  -   -   - Expired  (102,736)  100.48   - Exercised  -   -   - Outstanding, December 31, 2024  139,897  $11.25   0.79  The intrinsic value of the warrants as of December 31, 2024, is $0. All of the outstanding warrants are exercisable as of December 31, 2024. 2018 Equity Incentive Plan, as amended On January 1, 2024, the number of shares available under the Company’s 2018 Equity Incentive Plan, as amended (the “2018 Plan”) was increased by 478,344 shares of Common Stock. As of December 31, 2024, the 2018 Plan permits the Company to issue up to an aggregate of 1,529,223 shares of Common Stock of which 755,618 shares are available to be issued. Options granted during the year ended December 31, 2024 In January 2024, the Company granted options to an officer of the Company to purchase an aggregate of 92,000 shares of the Company’s Common Stock with an